Women who reported more frequent physical activity experienced significantly lower perimenopause symptom burden across ...
JoAnn Pinkerton, MD: Elinzanetant is a dual neurokinin receptor inhibitor. It's an NK1 and NK3 receptor antagonist, and what ...
OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and ...
Women receiving menopause hormone therapy (HT) alongside semaglutide experienced significantly greater weight loss than those ...
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use. Postmenopausal women using hormone therapy had ...
Long-acting cabotegravir and lenacapavir both deliver near-complete protection. The faculty compare dosing schedules, drug interactions, and injection site reactions, and share techniques that make ...
Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, ...
Women with moderate to severe vasomotor symptoms (VMS) who received elinzanetant (Lynkuet; Bayer) were more likely than those ...
CBT is an evidence-based, nonhormonal option endorsed by the National Institutes of Health and The Menopause Society for ...
Women who reached menopause before age 40 years had a higher long-term risk of cardiovascular disease (CVD) and coronary ...
Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results